MAGIQ THERAPEUTICS
MAGiQ Therapeutics focuses on the development and licensing of regenerative medicine products generated from iPS cells. Founded in April 2018 and is based in Yokohama-shi, Kanagawa, Japan.
MAGIQ THERAPEUTICS
Industry:
Biotechnology Pharmaceutical Therapeutics
Founded:
2018-04-01
Address:
Yokohama-shi, Kanagawa, Japan
Country:
Japan
Status:
Active
Current Advisors List
More informations about "MAGiQ Therapeutics"
MAGiQ Therapeutics - Crunchbase Company Profile & Funding
MAGiQ Therapeutics focuses on the development and licensing of regenerative medicine products generated from iPS cells. Founded in April 2018 and is based in Yokohama-shi, …See details»
MAGiQ Therapeutics - PitchBook
Developer of progenitor cells designed to treat demyelinating and degenerative diseases of the CNS (central nervous system). The company offers iPSC (induced pluripotent stem cells) …See details»
New Company, MAGiQ, Aims to Develop Stem Cell Therapies for …
Apr 26, 2018 · A new Japanese joint venture company called MAGiQ Therapeutics — the result of a collaboration between Q Therapeutics and Reprocell — aims to develop cell and gene …See details»
Q-cell GPR Cell Therapy - REPROCELL
MAGiQ and REPROCELL are working on the research and development of iGRP by combining Q Therapeutics’ technology and know-how on GRP cell with REPROCELL’s iPSC technology. About Dr. Mahendra Rao: Dr Rao is the …See details»
MAGiQ Therapeutics - Contacts, Employees, Board Members
MAGiQ Therapeutics focuses on the development and licensing of regenerative medicine products generated from iPS cells.See details»
MAGiQ Therapeutics - Crunchbase
MAGiQ Therapeutics focuses on the development and licensing of regenerative medicine products generated from iPS cells.See details»
MAGiQ Therapeutics KK - Drug pipelines, Patents, Clinical trials
Explore MAGiQ Therapeutics KK with its drug pipeline, therapeutic area, technology platform, .See details»
MAGiQ Therapeutics Inc. | YOKOHAMA STARTUP HUB | Yokohama …
MAGiQ Therapeutics Inc. Industry: Biotechnology; Address: KDX Shin-Yokohama 3 Building 8F, 11-381-9 Shin-Yokohama, Kohoku-ku, Yokohama City, Kanagawa Prefecture Inside Reprocell …See details»
Q Therapeutics Announces Joint Venture with REPROCELL: …
MAGiQ is a 50:50 joint venture, in which Q Therapeutics will contribute its patented technology to derive and manufacture glial-restricted progenitor (GRP) cells from any tissue source, …See details»
MAGiQ Therapeutics Inc - Company Profile and News
Company profile page for MAGiQ Therapeutics Inc including stock price, company news, executives, board members, and contact informationSee details»
Q Therapeutics, Inc. Announces Joint Venture With ReproCELL, Inc
Apr 23, 2018 · Q Therapeutics, Inc. and REPROCELL Inc. announced the formation of MAGiQ Therapeutics, Inc., a Japanese joint venture company. MAGiQ will develop iPSC-derived, glial …See details»
New Company, MAGiQ, Aims to Develop Stem Cell Therapies for …
A new Japanese joint venture company called MAGiQ Therapeutics ? the result of a collaboration between Q Therapeutics and Reprocell ? aims to develop cell and gene therapies for …See details»
Q Therapeutics Announces Joint Venture With REPROCELL
MAGiQ is a 50:50 joint venture, in which Q Therapeutics will contribute its patented technology to derive and manufacture glial-restricted progenitor (GRP) cells from any tissue source, …See details»
MAGiQ Therapeutics: Company in Japan, Asia - Sovereign Wealth …
MAGiQ Therapeutics is a Company located in Japan, Asia, and was founded in 2018.See details»
Research programme: glial restricted progenitor cell therapy
Glial restricted progenitor cells derived from induced pluripotent stem cells are being developed by MAGiQ Therapeutics, for the treatment of demyelinating andSee details»
Q Therapeutics Announces Joint Venture With REPROCELL
Apr 24, 2018 · MAGiQ will develop iPSC-derived, glial-restricted progenitor cells (GRPs), in collaboration with Q Therapeutics and REPROCELL, to treat demyelinating and degenerative …See details»
Q Therapeutics Company Profile 2024: Valuation, Funding
Developer of novel stem cell therapy intended to treat debilitating CNS disease and injury.See details»
Q Therapeutics Announces Joint Venture With REPROCELL
Apr 23, 2018 · MAGiQ will develop iPSC-derived, glial-restricted progenitor cells (GRPs), in collaboration with Q Therapeutics and REPROCELL, to treat demyelinating and degenerative …See details»
Magiq Technologies Revenue, Growth & Competitor Profile
Nov 18, 2024 · Magiq Technologies's Annual Report & Profile shows critical firmographic facts: What is the company's size? (Annual sales and employees) What industry is the company in? …See details»
Q Therapeutics Announces Joint Venture With REPROCELL
MAGiQ will develop iPSC-derived, glial-restricted progenitor cells (GRPs), in collaboration with Q Therapeutics and REPROCELL, to treat demyelinating and degenerative diseases of the CNS.See details»